Park Medi World: FY33 સુધીમાં 10,000 બેડની ક્ષમતા હાંસલ કરવાનો લક્ષ્યાંક!
NiveshIQ
NSE: PARKHOSPS · Healthcare
Park Medi World Ltd.
₹279.25▲ ₹1.60 (+0.58%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on PARKHOSPS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Park Medi World Ltd.
Park Medi World Limited operates a network of NABH accredited multi-super specialty hospitals under the Park brand name, providing services in internal medicine, neurology, urology, gastroenterology, general surgery, orthopedics, and oncology. Founded in 2005, the company is headquartered in Gurugram, India. Park Medi World Limited's core business is driven by its hospital network, which is a key revenue driver. The company's recent developments include the incorporation of a step-down subsidiary, which is expected to enhance its operational efficiency. Park Medi World Limited competes with other healthcare providers in the Indian market, but its strong brand presence and network of hospitals provide a competitive edge. The company's growth outlook is driven by the increasing demand for he
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,229 Cr -1.90% | ₹1,392 Cr +13.20% | ₹1,679 Cr |
| EBITDA Margin | 27.52% | 29.01% | 0.00% |
| Net Profit | ₹153.49 Cr -30.10% | ₹205.16 Cr +33.70% | ₹274.00 Cr |
| EPS | ₹3.55 | ₹4.75 | – |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Park Medi World: FY33 સુધીમાં 10,000 બેડની ક્ષમતા હાંસલ કરવાનો લક્ષ્યાંક!
Park Medi World Eyes 10,000 Bed Capacity by FY33
🔒
+ 3 more stories about Park Medi World Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹460 Cr, PAT ₹77 Cr, EPS ₹1.64. Growth context: revenue QoQ +12.2%, PAT QoQ +51.6%.
Key growth drivers for PARKHOSPS over the next 2-4 quarters will be patient volumes, occupancy, average revenue per occu...
FY25 (last completed FY): revenue ₹1, 392 Cr, PAT ₹205 Cr, EBITDA margin 29.0%, EPS ₹4.75. Year-on-year: revenue YoY +13...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for PARKHOSPS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track PARKHOSPS alongside your other holdings
Unlock full PARKHOSPS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Park Medi World Ltd.?
NiveshIQ detects active intelligence signals for Park Medi World Ltd. (PARKHOSPS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Park Medi World Ltd.?
Park Medi World Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,079,827.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.